Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2005

View Archived Issues

Antithrombotic efficacy of dual-acting MC-45308

Oxytocin receptor antagonists in the prevention of preterm labor

Renal impairment does not significantly affect the PK profile of oral naftidrofuryl

Anticoagulant and antiinflammatory effects of rhAT in healthy volunteers

Darifenacin improves quality of life of patients with overactive bladder

Recent patents cover novel treatments for cognitive disorders

Novel antiglaucoma agents jointly disclosed by Ube and Santen

Vanilloid VR1 receptor modulators emerge from recent R&D

Antiviral efficacy and pharmacokinetics of single-oral dose PA-457 reported in HIV-infected patients

Antiviral efficacy and pharmacokinetics of vicriviroc alone or in combination with other antivirals

Thiovir effective against resistant HIV-1 strains and synergistic with zidovudine

ImClone Systems and UCB enter partnership for CDP-791

Vicuron stockholders vote to approve acquisition by Pfizer

Dosing begins in phase I study of GS-9132 for HCV

Vaqta approved for children as young as 12 months of age

Pfizer completes acquisition of Bioren

Astellas reports discovery of novel reverse NCX inhibitor YM-270951

Predix begins pivotal study with PRX-00023 for generalized anxiety disorder

Akorn signs agreement for AK-1015

Alnylam awarded grant for Parkinson's research

Positive phase III results for Desilux

Migenix cleared to begin phase IIb study of MX-3253 in Canada

HuMax-CD20 enters phase II study for rheumatoid arthritis

Schering-Plough exercises rights to CNTO-148

Japanese approval for Amplatzer Septal Occluder for atrial septal occlusion

Promising preliminary results for HER-2 Protein AutoVac in breast cancer

Otsuka to launch Meptin Clickhaler in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...